Seasoned software industry leader to drive growth and adoption of the Appian Platform in the region ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

On October 21, 2024, the 2024 business EPS guidance was upgraded to growth of at least a low single-digit percentage at CER supported by the ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...

PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.

PARIS (Reuters) -Sanofi said on Monday it had entered exclusive talks for the sale of a 50% controlling stake in its consumer ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private ...

France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...